Mahadevan, U., Vermeire, S., Wolf, D. C., Forger, F., Cush, J. J., Golembesky, A., … Abbas, S. (2014). DOP024 Pregnancy outcomes after exposure to certolizumab pegol: Results from safety surveillance. Journal of Crohn’s and Colitis, 8, S26–S26. https://doi.org/10.1016/s1873-9946(14)60049-0

Mahadevan, U., S. Vermeire, D. C. Wolf, F. Forger, J. J. Cush, A. Golembesky, L. Shaughnessy, D. De Cuyper, and S. Abbas. “DOP024 Pregnancy outcomes after exposure to certolizumab pegol: Results from safety surveillance.” Journal of Crohn’s and Colitis 8 (February 2014): S26–S26. https://doi.org/10.1016/s1873-9946(14)60049-0.

Mahadevan U, Vermeire S, Wolf DC, Forger F, Cush JJ, Golembesky A, et al. DOP024 Pregnancy outcomes after exposure to certolizumab pegol: Results from safety surveillance. Journal of Crohn’s and Colitis. 2014 Feb;8:S26–S26.

Mahadevan, U., et al. “DOP024 Pregnancy outcomes after exposure to certolizumab pegol: Results from safety surveillance.” Journal of Crohn’s and Colitis, vol. 8, Oxford University Press (OUP), Feb. 2014, pp. S26–S26. Crossref, doi:10.1016/s1873-9946(14)60049-0.

Mahadevan U, Vermeire S, Wolf DC, Forger F, Cush JJ, Golembesky A, Shaughnessy L, De Cuyper D, Abbas S. DOP024 Pregnancy outcomes after exposure to certolizumab pegol: Results from safety surveillance. Journal of Crohn’s and Colitis. Oxford University Press (OUP); 2014 Feb;8:S26–S26.